Lurbinectedin, marketed under the brand name Zepzelca, is a chemotherapy drug used for the treatment of metastatic small cell lung cancer (SCLC) in patients who have previously received chemotherapy [3]. According to DrugPatentWatch, there are no alternative drugs or formulations to Lurbinectedin currently on the market [1].

However, there are other treatment options available for SCLC. These include chemotherapy drugs such as etoposide and cisplatin, immunotherapy drugs such as atezolizumab and durvalumab, and radiation therapy [3]. In addition, clinical trials are ongoing to investigate the efficacy of new drugs and treatment combinations for SCLC [2].

One such trial is investigating the combination of lurbinectedin and doxorubicin, another chemotherapy drug, for the treatment of SCLC [2]. Another trial is investigating the combination of lurbinectedin and pembrolizumab, an immunotherapy drug, for the treatment of advanced solid tumors [2].

In conclusion, while there are currently no alternative drugs or formulations to Lurbinectedin on the market, there are other treatment options available for SCLC, including chemotherapy, immunotherapy, and radiation therapy. Clinical trials are also ongoing to investigate the efficacy of new drugs and treatment combinations for SCLC. Patients should discuss all available treatment options with their healthcare provider to determine the best course of treatment for their individual needs.

Sources:
[1] DrugPatentWatch. Lurbinectedin Tradename: ZEPZELCA. https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN.
[2] PubMed. Lurbinectedin. https://pubmed.ncbi.nlm.nih.gov/32055920/.
[3] Medscape. Lurbinectedin (Zepzelca). https://reference.medscape.com/drug/zepzelca-lurbinectedin-4000075.